These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34713519)

  • 1. The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin.
    Bril SI; Al-Mamgani A; Chargi N; Remeijer P; Devriese LA; de Boer JP; de Bree R
    Head Neck; 2022 Jan; 44(1):189-200. PubMed ID: 34713519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer.
    Wendrich AW; Swartz JE; Bril SI; Wegner I; de Graeff A; Smid EJ; de Bree R; Pothen AJ
    Oral Oncol; 2017 Aug; 71():26-33. PubMed ID: 28688687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol.
    Schaeffers AWMA; Devriese LA; van Gils CH; Dankbaar JW; Voortman J; de Boer JP; Slingerland M; Hendriks MP; Smid EJ; Frederix GWJ; de Bree R
    PLoS One; 2023; 18(11):e0294147. PubMed ID: 38011186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer.
    Chargi N; Bashiri F; Wendrich AW; Smid EJ; de Jong PA; Huitema ADR; Devriese LA; de Bree R
    Eur Arch Otorhinolaryngol; 2022 Jul; 279(7):3685-3694. PubMed ID: 35038029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: The prospective PLATISMA study.
    Chargi N; Molenaar-Kuijsten L; Huiskamp LFJ; Devriese LA; de Bree R; Huitema ADR
    Eur J Cancer; 2022 Jan; 160():92-99. PubMed ID: 34810046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low Skeletal Muscle Mass Is a Risk Factor for Aspiration Pneumonia During Chemoradiotherapy.
    Endo K; Ueno T; Hirai N; Komori T; Nakanishi Y; Kondo S; Wakisaka N; Yoshizaki T
    Laryngoscope; 2021 May; 131(5):E1524-E1529. PubMed ID: 33030229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The predictive and prognostic value of low skeletal muscle mass for dose-limiting toxicity and survival in head and neck cancer patients receiving concomitant cetuximab and radiotherapy.
    Huiskamp LFJ; Chargi N; Devriese LA; de Jong PA; de Bree R
    Eur Arch Otorhinolaryngol; 2020 Oct; 277(10):2847-2858. PubMed ID: 32335709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of relative cisplatin dose to skeletal muscle mass on adverse events in patients with head and neck cancer undergoing chemoradiotherapy.
    Suzuki S; Yokota T; Notsu A; Hamauchi S; Onozawa Y; Fushiki K; Oshima K; Kawakami T; Tsushima T; Yasui H; Ogawa H; Onoe T; Kawatani K; Yamazaki K
    Oncologist; 2024 Jul; ():. PubMed ID: 38979778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns, Predictors, and Prognostic Value of Skeletal Muscle Mass Loss in Patients with Locally Advanced Head and Neck Cancer Undergoing Cisplatin-Based Chemoradiotherapy.
    Chargi N; Wegner I; Markazi N; Smid E; de Jong P; Devriese L; de Bree R
    J Clin Med; 2021 Apr; 10(8):. PubMed ID: 33919607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low skeletal muscle mass is predictive of dose-limiting toxicities in head and neck cancer patients undergoing low-dose weekly cisplatin chemoradiotherapy.
    Becker JN; Hermann R; Wichmann J; Sonnhoff M; Christiansen H; Bruns F
    PLoS One; 2023; 18(2):e0282015. PubMed ID: 36802403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
    van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW
    BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
    Kim R; Hahn S; Shin J; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS
    Cancer Res Treat; 2016 Jul; 48(3):907-16. PubMed ID: 26582394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin.
    Patimarattananan T; Nongnuch A; Pattaranutaporn P; Unwanatham N; Jiarpinitnun C; Ngamphaiboon N
    Support Care Cancer; 2021 Feb; 29(2):877-887. PubMed ID: 32524284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.
    Driessen CM; de Boer JP; Gelderblom H; Rasch CR; de Jong MA; Verbist BM; Melchers WJ; Tesselaar ME; van der Graaf WT; Kaanders JH; van Herpen CM
    Eur J Cancer; 2016 Jan; 52():77-84. PubMed ID: 26655558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-dependent hemato- and nephrotoxicity in patients with head and neck cancer receiving chemoradiotherapy with weekly cisplatin.
    Weykamp F; Seidensaal K; Rieken S; Green K; Mende S; Zaoui K; Freier K; Adeberg S; Debus J; Welte SE
    Strahlenther Onkol; 2020 Jun; 196(6):515-521. PubMed ID: 31784802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
    de Souza Viana L; de Aguiar Silva FC; Andrade Dos Anjos Jacome A; Calheiros Campelo Maia D; Duarte de Mattos M; Arthur Jacinto A; Elias Mamere A; Boldrini Junior D; de Castro Capuzzo R; Roberto Santos C; Lopes Carvalho A
    Head Neck; 2016 Apr; 38 Suppl 1():E970-80. PubMed ID: 26031625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients.
    de Jong C; Chargi N; Herder GJM; van Haarlem SWA; van der Meer F; van Lindert ASR; Ten Heuvel A; Brouwer J; de Jong PA; Devriese LA; Huitema ADR; Egberts TCG; de Bree R; Deneer VHM
    J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1554-1564. PubMed ID: 35301821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
    Teo M; Karakaya E; Young CA; Dyker KE; Coyle C; Sen M; Prestwich RJ
    Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):647-53. PubMed ID: 23948462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer.
    Okano S; Enokida T; Onoe T; Ota Y; Motegi A; Zenda S; Akimoto T; Tahara M
    Int J Clin Oncol; 2019 Jul; 24(7):789-797. PubMed ID: 30796560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
    Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
    Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.